2023 World Conference on Lung Cancer (Posters)-P2.05. The Power for PD-L1 Expression to Predict Immune Checkpoint Blockade Outcomes is Determined by Tumor Transcriptome

P2.05. The Power for PD-L1 Expression to Predict Immune Checkpoint Blockade Outcomes is Determined by Tumor Transcriptome - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the WCLC 2023 conference investigated the predictive ability of PD-L1 expression for immune checkpoint inhibitors (ICI) in metastatic non-small cell lung cancer (NSCLC). The researchers hypothesized that the heterogeneity of tumor transcriptome could explain the variations in PD-L1 performance. They conducted a cross-cancer correlative analysis and a multivariate Cox interaction test to evaluate the variability of PD-L1 predictive value explained by immune-related genes. <br /><br />The study developed a transcriptomics-based PD-L1 power model using RNA-seq and clinical data from NSCLC and bladder cancer trials. The model classified cancer types into two groups based on their PD-L1 predictiveness for ICI: Power-High and Power-Low. In the Power-High group, PD-L1 tumors showed better overall survival and objective response rate with ICI compared to PD-L1 negative tumors. Conversely, in the Power-Low group, PD-L1 negative tumors had better outcomes with ICI. These findings were consistent across different trials and immune subtypes.<br /><br />The study concluded that the predictive capacity of PD-L1 expression for ICI is context-dependent and can be confounded by tumor transcriptome. The researchers emphasized the importance of considering PD-L1 power in treatment decisions and trial design. They suggested that classifying patients based on PD-L1 power could optimize the use of PD-L1 expression as a biomarker in clinical settings. Further research is needed to understand the mechanisms underlying the distinct PD-L1 power.<br /><br />In summary, this study highlights the variability of PD-L1 predictive ability in metastatic NSCLC and suggests that tumor transcriptome plays a role in determining the efficacy of immune checkpoint blockade. The findings emphasize the need for personalized treatment approaches and caution against overreliance on PD-L1 expression alone as a biomarker for ICI response.

Asset Subtitle

Anlin Li

Meta Tag

Speaker Anlin Li

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

WCLC 2023 conference

PD-L1 expression

immune checkpoint inhibitors

metastatic non-small cell lung cancer

tumor transcriptome

cross-cancer correlative analysis

multivariate Cox interaction test

transcriptomics-based PD-L1 power model

overall survival

objective response rate